Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 399 participants.
Also called NCT02926937
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 399 participants
- Sponsor
- Registry
-
NCT02926937 -
2016-001799-31
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Mexico
- Registry status
- Completed
Technical summary
Registry record NCT02926937. Randomized; double masking; primary purpose treatment. Start 2016-11-11 (actual); primary completion 2019-04-22 (actual). Results posted on 2021-06-21.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Sotagliflozin (SAR439954)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Lexicon Pharmaceuticals
- Collaborator
- Sanofi
Record details
- Record id
cardio:ct-nct02926937- Content hash
7d30b7d6b6b5aba660a8711e8e3069f1d4825440a38a4300a2b35242ed112572